Anti-Inflammatory interventions in end-stage kidney disease: A randomized, double-blinded, controlled and crossover clinical trial on the use of pravastatin in continuous ambulatory peritoneal dialysis

Archives of Medical Research

Volumn 44, Issue 8, 2013, Pages 633-637

  Cueto Manzano, Alfonso M ^a   Ángel Zúñiga, Juan R ^a   Ornelas Carrillo, Gabina ^b   Rojas Campos, Enrique ^a   Martínez Ramírez, Héctor R ^a   Cortés Sanabria, Laura ^a  

^a Specialties Hospital   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

C reactive protein; Continuous ambulatory peritoneal dialysis; Crossover clinical trial; Inflammation; Pravastatin

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT DURATION;

C-REACTIVE PROTEIN; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CROSSOVER CLINICAL TRIAL; INFLAMMATION; PRAVASTATIN;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MEXICO; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PLACEBOS; PRAVASTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84889560857     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.10.016     Document Type: Article

References (30)

1. Arici M., Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?. Kidney Int 2001, 59:407-414.
2. Pecoits-Filho R., Lindholm B., Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant 2002, 17(suppl 11):28-31.
3. Wanner C., Zimmermann J., Schwedler S., et al. Inflammation and cardiovascular risk in dialysis patients. Kidney Int 2002, 61(suppl 80):S99-S102.
4. The United States Renal Data System. Annual Data Report. 2012. (15 July 2013 date last accessed). http://www.usrds.org.
5. Vidt D.G. Inflammation in renal disease. Am J Cardiol 2006, 97(suppl 1):20A-27A.
6. Kalaitzidis R.G., Elisaf M.S. The role of statins in chronic kidney disease. Am J Nephrol 2011, 34:195-202.
7. Navaneethan S.D., Pansini F., Perkovic V., et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009, 2:CD007784.
8. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
9. Fellström B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407. AURORA Study Group.
10. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
11. Antonopoulos A.S., Margaritis M., Lee R., et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012, 18:1519-1530.
12. Krane V., Winkler K., Drechsler C., et al. for the German Diabetes and Dialysis Study Investigators. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 2008, 74:1461-1467.
13. Chang J.W., Yang W.S., Min W.K., et al. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002, 39:1213-1217.
14. Cueto-Manzano A.M., Rojas-Campos E., Martínez-Ramírez H.R., et al. Can the inflammation markers of patients with high peritoneal permeability on continuous ambulatory peritoneal dialysis be reduced on nocturnal intermittent peritoneal dialysis?. Perit Dial Int 2006, 26:341-348.
15. Cueto-Manzano A.M., Quintana-Piña E., Correa-Rotter R. Long-term CAPD survival and analysis of mortality risk factors: 12-year experience of a single center. Perit Dial Int 2001, 21:148-153.
16. Rojas-Campos E., Alcántar-Medina M., Cortés-Sanabria L., et al. Patient and technique survival in continuous ambulatory peritoneal dialysis in a single center of the west of Mexico. Rev Invest Clin 2007, 59:184-191.
17. Cueto-Manzano A.M., González-Espinoza L., Martín-del-Campo F., et al. Inflammation in peritoneal dialysis: a Latin American perspective. Perit Dial Int 2007, 27:347-352.
18. Kumar S., Raftery M., Yaqoob M., et al. Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients. Perit Dial Int 2007, 27:283-287.
19. Sezer M.T., Katirci S., Demir M., et al. Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients. Scand J Urol Nephrol 2007, 41:436-441.
20. Sibbald B. Understanding controlled trials. Crossover trials. BMJ 1998, 316:1719.
21. Ascer E., Bertolami M.C., Venturinelli M.L., et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004, 177:161-166.
22. van de Ree M.A., Huisman M.V., Princen H.M., et al. Strong decrease of high sensitivity C-reactive protein with high dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003, 166:129-135.
23. Antoniades C., Bakogiannis C., Leeson P., et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin mediated endothelial nitric oxide synthase coupling. Circulation 2011, 124:335-345.
24. Jarvisalo M.J., Toikka J.O., Vasankari T., et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999, 147:237-242.
25. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
26. Schonbeck U., Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation 2004, 109(21suppl 1):II18-II26.
27. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
28. Verma S., Wang C.H., Li S.H., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919.
29. Devaraj S., Xu D.Y., Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107:398-404.
30. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.